News 06.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an...
News 02.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners”), and Orano Med, a...
News 01.07.2026 PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused...
News 29.06.2026 Neurimmune announced today that safety and efficacy data of the long-term follow up of the NI006-101 trial of cliramitug (formerly NI006, ALXN2220) for the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM) have been published in Nature Medicine by Peter C. Kahr et al.1 ATTR-CM is a systemic and potentially life-threatening disease caused by...
News 23.06.2026 Switzerland, 23 June 2026 – CUTISS, a late-stage clinical company at the forefront of tissue therapeutics and regenerative medicine, has announced the election of Dr. Achim von Leoprechting as Chairman of its Board of Directors. Dr. von Leoprechting succeeds Prof. Martin Meuli, co-founder, who has chaired the CUTISS Board since the company’s...